Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Advantus Health Partners (“Advantus”), to provide access of Elutia’s EluPro™ Antibiotic Eluting BioEnvelope to Advantus’ core group purchasing organizations (GPO) solutions portfolio. “Teaming up with Advantus is another major step forward in meeting ...

— Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — SILVER SPRING, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of new preclinical data in the current issue of Antibiotics, further demonstrating the antimicrobial performance of its antibiotic-eluting biologic envelope de ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 Elutia Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer March 6, 2025 Forward-Looking Statements This presentation of Elutia Inc. ("Elutia," "we," "us," "our" or the "Company") (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical facts, including but not limited to statements regarding the launch and market reception of EluPro®, including the tim ...

Elutia Inc. (NASDAQ:ELUT) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants David Carey – FINN Partners C. Randal Mills – Chief Executive Officer Matt Ferguson – Chief Financial Officer Conference Call Participants Ross Osborn – Cantor Fitzgerald Frank Takkinen – Lake Street Capital Markets Operator Good afternoon, ladies and gentlemen. Welcome to the Elutia Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. Please be advised that today's conference call i ...

Elutia (ELUT) Q4 2024 Earnings Call March 07, 2025 01:31 AM ET Company Participants David Carey - Senior PartnerRandy Mills - President & CEOMatthew Ferguson - CFO Conference Call Participants Ross Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsFrank Takkinen - Senior Research Analyst Operator I would now like to hand the conference call over to David Carey, Fin FIN Partners. Please go ahead. David Carey Thank you, operator, and thank you all for participating in today's call. Earlier tod ...

Sales Performance - Overall BioEnvelope sales increased by 18%, with same-center sales rising by 65% following the commercialization of EluPro[1] - EluPro accounted for over 30% of BioEnvelope sales in the fourth quarter, indicating strong initial market uptake[4] - Net sales for BioEnvelope products, including EluPro and CanGaroo, totaled $9.9 million for the full year 2024, a 5% increase from $9.4 million in 2023[5] - Net sales of SimpliDerm increased by 12% to $11.6 million, compared to $10.3 million in 2023[5] - Net sales for Q4 2024 were $5,468 million, a decrease of 6.9% compared to $5,875 million in Q4 2023[15] Financial Performance - Net loss from continuing operations was $54.1 million for the full year 2024, compared to a loss of $41.2 million in 2023[8] - Cash balance as of December 31, 2024, was $13.2 million, following a registered direct offering that raised approximately $15 million[8] - Gross margin on a GAAP basis was 43.9% for the full year 2024, down from 44.7% in 2023[8] - Net loss for Q4 2024 was $9,061 million, compared to a net loss of $9,316 million in Q4 2023, showing a 2.7% improvement[15] Operating Expenses - Total operating expenses for the fourth quarter were $10.8 million, compared to $10.6 million in the same period of 2023[8] - Total operating expenses for Q4 2024 were $10,756 million, an increase of 1.2% from $10,631 million in Q4 2023[15] - Research and development expenses for Q4 2024 were $834 million, down 39.5% from $1,381 million in Q4 2023[15] - FiberCel litigation costs for Q4 2024 were $2,611 million, slightly down from $2,711 million in Q4 2023[15] Profitability Metrics - Adjusted EBITDA for the fourth quarter was a loss of $3.8 million, an improvement from a loss of $4.5 million in the same period of 2023[8] - Adjusted gross profit (Non-GAAP) for Q4 2024 was $3,175 million, up 6.7% from $2,975 million in Q4 2023[16] - Adjusted gross margin percentage (Non-GAAP) for Q4 2024 was 58.1%, compared to 50.6% in Q4 2023[16] - EBITDA (Non-GAAP) for Q4 2024 was $(7,126) million, a decline from $(6,922) million in Q4 2023[18] - Adjusted EBITDA (Non-GAAP) for Q4 2024 was $(3,751) million, an improvement from $(4,453) million in Q4 2023[18] Product Development - The company had 67 approved EluPro accounts by the end of 2024, averaging more than 15 new approvals per month[4] - Gross profit for Q4 2024 increased to $2,324 million, up 9.4% from $2,124 million in Q4 2023[15]

Core Viewpoint - Elutia Inc. reported strong sales growth driven by the successful pilot launch of EluPro, an FDA-cleared antibiotic-eluting biomatrix, which has gained significant traction in the market [3][4]. Business Highlights - EluPro accounted for over 30% of BioEnvelope sales in the fourth quarter, indicating robust initial market uptake [5]. - The company ended 2024 with 67 approved EluPro accounts, averaging more than 15 new approvals per month [5]. - Sales growth is supported by agreements with major national group purchasing organizations (GPOs) [5]. - Independent sales agents contributed 45% of BioEnvelope sales from EluPro, showcasing the scalability of the sales model [5]. - Elutia raised approximately $15 million in a registered direct offering, enhancing its financial position [5]. Financial Results - For the full year 2024, net sales for BioEnvelope products increased by 5% to $9.9 million compared to $9.4 million in 2023 [6]. - SimpliDerm net sales rose by 12% to $11.6 million, while cardiovascular product sales decreased by 42% to $2.9 million [6]. - Overall net sales decreased by 1.5% to $24.4 million, driven by changes in the cardiovascular sales model [6]. - Gross margin on a GAAP basis was 43.9%, down from 44.7% [6]. - Total operating expenses increased to $46.4 million from $41.6 million, with a net loss from continuing operations of $54.1 million compared to a loss of $41.2 million in 2023 [6]. Quarterly Performance - In Q4 2024, net sales for BioEnvelope products increased by 18% to $2.7 million compared to $2.3 million in Q4 2023 [10]. - SimpliDerm sales decreased by 23% to $2.3 million, while cardiovascular product sales fell by 20% to $0.5 million [10]. - Overall net sales for the quarter decreased by 7% to $5.5 million [10]. - Gross margin on a GAAP basis improved to 42.5% from 36.2% [10]. - Adjusted EBITDA for Q4 was a loss of $3.8 million, an improvement from a loss of $4.5 million in the same period last year [10].

Core Viewpoint - Elutia Inc. is set to release its fourth quarter and full year 2024 financial results on March 6, 2025, with a conference call scheduled for the same day [1]. Company Overview - Elutia specializes in developing and commercializing drug-eluting biomatrix products aimed at enhancing the compatibility of medical devices with patients [3]. - The company is focused on addressing the needs of a growing population requiring implantable technologies, with a mission to humanize medicine for better patient outcomes [3]. Conference Call Details - The conference call will begin at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on March 6, 2025 [1]. - Access information for the call includes a U.S. investor line at 877-407-8029 and an international line at 201-689-8029, with a Conference ID of 13751810 [2]. - A live and archived webcast will be available on the "Investors" section of Elutia's website [2].

Core Viewpoint - Elutia Inc. has announced a definitive agreement for a registered direct offering of shares and prefunded warrants, aiming to raise approximately $15.0 million in gross proceeds [1][2]. Group 1: Offering Details - The company will sell 5,520,000 shares of Class A common stock at a price of $2.50 per share [1]. - Additionally, 480,000 prefunded warrants will be sold at a price of $2.499 each, which are immediately exercisable at an exercise price of $0.001 [1]. - The offering is expected to close on or about February 4, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - Elutia intends to utilize the proceeds from the offering for working capital and other general corporate purposes [2]. Group 3: Regulatory Information - The securities are being offered under an effective shelf registration statement on Form S-3, previously filed with the SEC [3]. - The offering will be made only by means of a prospectus supplement that is part of the registration statement [3].